Reference : Anti-TNF and Crohn's Disease: When Should We Stop?
Scientific journals : Article
Human health sciences : Gastroenterology & hepatology
http://hdl.handle.net/2268/85378
Anti-TNF and Crohn's Disease: When Should We Stop?
English
Louis, Edouard mailto [Université de Liège - ULg > Département des sciences cliniques > Hépato-gastroentérologie - Relations académiques et scientifiques (Médecine) >]
Belaiche, Jacques [Centre Hospitalier Universitaire de Liège - CHU > > Gastro-Entérologie-Hépatologie >]
Reenaers, Catherine [Centre Hospitalier Universitaire de Liège - CHU > > Gastro-Entérologie-Hépatologie >]
2009
Current Drug Targets
Bentham Science Publishers Ltd.
11
2
148-51
Yes
International
1389-4501
1873-5592
Sharjah
United Arab Emirates
[en] Crohn Disease/drug therapy/physiopathology
[en] When to stop anti-TNF therapy in Crohn's disease (CD)? This is a very important question both for patients and physicians. There is no published evidence to clearly and definitely answer this question. However data on natural history of CD, long term safety of biologics, outcome after immunosuppressors (IS) cessation and some preliminary studies on biologics cessation may help us to discuss this topic. One could argue that there is currently no good reason to stop anti-TNF therapy in a patient who is in stable remission and tolerate this drug very well. The decision to stop an anti-TNF treatment is thus currently based on a compromise between the benefits/risks and cost of such long term treatment. While it appears now clearly that prolonged anti-TNF therapy is associated with favourable outcome with sustained remission, reduced surgeries and hospitalisation as well as absence of significant increase in mortality or cancers, the cost-effectiveness which is probably favourable for short and mid-term treatment (up to one year), may be less optimal for very long term treatment. In this perspective however, prospective studies should be performed to adequately assess long term evolution, disease outcome, safety and global cost of strategies based on treatment reduction with IS maintenance alone or even full treatment cessation.
http://hdl.handle.net/2268/85378
also: http://hdl.handle.net/2268/14642

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Open access
PostPAut-Anti-TNF...when should we stop 2009-Current Drug Targets.pdfAuthor postprint124.86 kBView/Open

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.